Full-Time

Senior/Staff Software Engineer

Full Stack

Confirmed live in the last 24 hours

Dyno Therapeutics

Dyno Therapeutics

51-200 employees

Develops AI-optimized AAV vectors for gene therapy

AI & Machine Learning
Biotechnology
Healthcare

Mid, Senior

Belmont, MA, USA

Strong preference for candidates based in NYC or Greater Boston for occasional in-person engagements.

Category
Full-Stack Engineering
Software Engineering
Required Skills
Python
React.js
Vue.js
FastAPI
Flask
Django
Requirements
  • Strong programming and system design fundamentals with 4+ years of experience with full stack development.
  • Developing frontend applications using modern frameworks such as React (or other comparable frameworks such as Vue.js, Svelte, etc.).
  • Backend system design & development from DB to API.
  • Experience working cross-team to communicate with both technical and business stakeholders as well as customers.
  • Experience with Python backend development (examples include: Django, FastAPI, Flask, etc.).
  • Demonstrated examples of applying product taste.
  • Excitement about (but not necessarily experience with) building products that let scientists do more, faster.
  • Experience building on top of ML models and/or LLMs.
  • Have built products in the 0-1 stage.
  • Even limited experience managing cloud deployments and environments.
  • Excited to learn about bio/gene therapy (no experience necessary).
Responsibilities
  • Lead end-to-end development of new products for genetic sequence design within the ML Products team.
  • Iterating on ideas and prototypes and then prioritizing the path to an MVP.
  • Develop and disseminate best practices for repeatable and scalable end to end product development.
  • Collaborate with team members ranging from engineers, computational biologists, ML researchers, and biologists to come up with and build great products.
  • Mentor and teach other engineers on the team.

Dyno Therapeutics focuses on improving gene therapy by creating Adeno-associated virus (AAV) vectors, which are essential for delivering genetic material into cells. Their technology utilizes Artificial Intelligence to design and optimize these vectors, enhancing the effectiveness of gene therapies. Unlike many competitors, Dyno's unique approach combines AI with biotechnology, allowing for tailored solutions that meet the specific needs of pharmaceutical and biotech companies. Their goal is to collaborate with these companies to develop better gene therapies for various diseases, including those affecting muscles, the central nervous system, liver, and eyes.

Company Stage

Series A

Total Funding

$106M

Headquarters

Watertown, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

-10%

1 year growth

-13%

2 year growth

-4%
Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven capsid design significantly outperforms traditional methods, boosting efficiency.
  • Collaboration with NVIDIA accelerates high-performance biological sequence design.
  • Generative AI increases efficiency for eye and brain-targeted capsids, advancing gene delivery.

What critics are saying

  • Gene therapy investment slowdown may impact Dyno's growth and innovation funding.
  • Manufacturing bottlenecks could delay product development and deter investors.
  • High gene therapy costs may limit market adoption despite technological advancements.

What makes Dyno Therapeutics unique

  • Dyno uses AI to design optimized AAV vectors for gene therapy.
  • Their AI platform improves gene delivery efficiency for eye, muscle, and brain targets.
  • Partnerships with major pharma companies enhance Dyno's market presence and credibility.

Help us improve and share your feedback! Did you find this helpful?